Cytokinetics (CYTK) presented data from the Phase 1 study of CK-4021586, or CK-586. The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics of single and multiple oral doses of CK-586. The company said the data support the advancement of CK-586 to a Phase 2 trial in patients with heart failure with preserved ejection fraction which is expected to begin in fourth quarter, 2024.
"The results from this Phase 1 study replicate pre-clinical findings that show CK-586 directly reduces cardiac contractility at the level of the sarcomere. Importantly, CK-586 was observed to have a shallow and predictable PK/PD relationship and half-life that enables a once-daily fixed dosing regimen in patients with HFpEF," said Stuart Kupfer, Senior Vice President, Chief Medical Officer.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.